Which has preferable earnings & valuation, FATE or UPXI?

Upexi has higher revenue and earnings than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than Upexi, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fate Therapeutics $6.65M 34.71 -$136.32M -$1.09 N/A Upexi $15.81M 4.21 -$13.68M -$0.62 N/A

Is FATE or UPXI more profitable?

Upexi has a net margin of -874.00% compared to Fate Therapeutics' net margin of -2,056.79%. Fate Therapeutics' return on equity of -58.89% beat Upexi's return on equity. Company Net Margins Return on Equity Return on Assets Fate Therapeutics -2,056.79% -58.89% -39.39% Upexi -874.00% -66.70% -19.56%

Which has better earnings and valuation, UPXI or ORGO?

Organogenesis has higher revenue and earnings than Upexi. Organogenesis is trading at a lower price-to-earnings ratio than Upexi, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Upexi $15.81M 4.21 -$13.68M -$0.62 N/A Organogenesis $564.17M 0.55 $37.03M -$0.19 N/A

Is UPXI or ORGO more profitable?

Organogenesis has a net margin of -0.84% compared to Upexi's net margin of -874.00%. Organogenesis' return on equity of 9.63% beat Upexi's return on equity. Company Net Margins Return on Equity Return on Assets Upexi -874.00% -66.70% -19.56% Organogenesis -0.84% 9.63% 4.76%

Upexi (UPXI) Competitors

$0.95 -0.07 (-7.12%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$0.94 0.00 (-0.36%)

As of 06/5/2026 07:59 PM Eastern

Compare

UPXI vs. FATE, ORGO, ABEO, BCYC, and DMAC

Should you buy Upexi stock or one of its competitors? MarketBeat compares Upexi with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Upexi include Fate Therapeutics (FATE), Organogenesis (ORGO), Abeona Therapeutics (ABEO), Bicycle Therapeutics (BCYC), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical products" industry.

How does Upexi compare to Fate Therapeutics?

Fate Therapeutics (NASDAQ:FATE) and Upexi (NASDAQ:UPXI) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

Upexi has higher revenue and earnings than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than Upexi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fate Therapeutics	$6.65M	34.71	-$136.32M	-$1.09	N/A
Upexi	$15.81M	4.21	-$13.68M	-$0.62	N/A

Fate Therapeutics has a beta of 2.53, suggesting that its share price is 153% more volatile than the broader market. Comparatively, Upexi has a beta of -0.35, suggesting that its share price is 135% less volatile than the broader market.

Upexi has a net margin of -874.00% compared to Fate Therapeutics' net margin of -2,056.79%. Fate Therapeutics' return on equity of -58.89% beat Upexi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%
Upexi	-874.00%	-66.70%	-19.56%

Fate Therapeutics presently has a consensus target price of $5.13, indicating a potential upside of 158.84%. Upexi has a consensus target price of $8.33, indicating a potential upside of 779.60%. Given Upexi's stronger consensus rating and higher probable upside, analysts plainly believe Upexi is more favorable than Fate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Upexi	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Fate Therapeutics had 5 more articles in the media than Upexi. MarketBeat recorded 5 mentions for Fate Therapeutics and 0 mentions for Upexi. Fate Therapeutics' average media sentiment score of 0.00 equaled Upexi'saverage media sentiment score.

Company	Overall Sentiment
Fate Therapeutics	Neutral
Upexi	Neutral

97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 5.7% of Upexi shares are held by institutional investors. 4.7% of Fate Therapeutics shares are held by company insiders. Comparatively, 9.0% of Upexi shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Upexi beats Fate Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Upexi compare to Organogenesis?

Upexi (NASDAQ:UPXI) and Organogenesis (NASDAQ:ORGO) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

Upexi currently has a consensus price target of $8.33, indicating a potential upside of 779.60%. Organogenesis has a consensus price target of $5.75, indicating a potential upside of 137.60%. Given Upexi's stronger consensus rating and higher possible upside, research analysts plainly believe Upexi is more favorable than Organogenesis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upexi	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Upexi has a beta of -0.35, indicating that its stock price is 135% less volatile than the broader market. Comparatively, Organogenesis has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market.

Organogenesis has higher revenue and earnings than Upexi. Organogenesis is trading at a lower price-to-earnings ratio than Upexi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upexi	$15.81M	4.21	-$13.68M	-$0.62	N/A
Organogenesis	$564.17M	0.55	$37.03M	-$0.19	N/A

Organogenesis has a net margin of -0.84% compared to Upexi's net margin of -874.00%. Organogenesis' return on equity of 9.63% beat Upexi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upexi	-874.00%	-66.70%	-19.56%
Organogenesis	-0.84%	9.63%	4.76%

In the previous week, Organogenesis' average media sentiment score of 0.59 beat Upexi's score of 0.00 indicating that Organogenesis is being referred to more favorably in the news media.

Company	Overall Sentiment
Upexi	Neutral
Organogenesis	Positive

5.7% of Upexi shares are held by institutional investors. Comparatively, 49.6% of Organogenesis shares are held by institutional investors. 9.0% of Upexi shares are held by insiders. Comparatively, 33.0% of Organogenesis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Organogenesis beats Upexi on 10 of the 15 factors compared between the two stocks.

How does Upexi compare to Abeona Therapeutics?

Abeona Therapeutics (NASDAQ:ABEO) and Upexi (NASDAQ:UPXI) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

Abeona Therapeutics currently has a consensus target price of $19.00, indicating a potential upside of 247.99%. Upexi has a consensus target price of $8.33, indicating a potential upside of 779.60%. Given Upexi's stronger consensus rating and higher probable upside, analysts clearly believe Upexi is more favorable than Abeona Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Upexi	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Abeona Therapeutics had 3 more articles in the media than Upexi. MarketBeat recorded 3 mentions for Abeona Therapeutics and 0 mentions for Upexi. Abeona Therapeutics' average media sentiment score of 0.46 beat Upexi's score of 0.00 indicating that Abeona Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Abeona Therapeutics	Neutral
Upexi	Neutral

Abeona Therapeutics has higher earnings, but lower revenue than Upexi. Upexi is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abeona Therapeutics	$5.82M	53.46	$71.18M	$0.97	5.63
Upexi	$15.81M	4.21	-$13.68M	-$0.62	N/A

Abeona Therapeutics has a net margin of 0.00% compared to Upexi's net margin of -874.00%. Abeona Therapeutics' return on equity of -53.98% beat Upexi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abeona Therapeutics	N/A	-53.98%	-38.52%
Upexi	-874.00%	-66.70%	-19.56%

Abeona Therapeutics has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market. Comparatively, Upexi has a beta of -0.35, meaning that its stock price is 135% less volatile than the broader market.

80.6% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 5.7% of Upexi shares are owned by institutional investors. 7.1% of Abeona Therapeutics shares are owned by company insiders. Comparatively, 9.0% of Upexi shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Abeona Therapeutics beats Upexi on 11 of the 17 factors compared between the two stocks.

How does Upexi compare to Bicycle Therapeutics?

Bicycle Therapeutics (NASDAQ:BCYC) and Upexi (NASDAQ:UPXI) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

Upexi has lower revenue, but higher earnings than Bicycle Therapeutics. Upexi is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$72.86M	4.02	-$218.96M	-$3.15	N/A
Upexi	$15.81M	4.21	-$13.68M	-$0.62	N/A

Bicycle Therapeutics has a net margin of -344.95% compared to Upexi's net margin of -874.00%. Bicycle Therapeutics' return on equity of -35.74% beat Upexi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%
Upexi	-874.00%	-66.70%	-19.56%

In the previous week, Bicycle Therapeutics had 3 more articles in the media than Upexi. MarketBeat recorded 3 mentions for Bicycle Therapeutics and 0 mentions for Upexi. Bicycle Therapeutics' average media sentiment score of 0.33 beat Upexi's score of 0.00 indicating that Bicycle Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Bicycle Therapeutics	Neutral
Upexi	Neutral

Bicycle Therapeutics presently has a consensus price target of $14.00, suggesting a potential upside of 233.33%. Upexi has a consensus price target of $8.33, suggesting a potential upside of 779.60%. Given Upexi's stronger consensus rating and higher probable upside, analysts clearly believe Upexi is more favorable than Bicycle Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Upexi	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

86.2% of Bicycle Therapeutics shares are held by institutional investors. Comparatively, 5.7% of Upexi shares are held by institutional investors. 22.9% of Bicycle Therapeutics shares are held by company insiders. Comparatively, 9.0% of Upexi shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Bicycle Therapeutics has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market. Comparatively, Upexi has a beta of -0.35, indicating that its stock price is 135% less volatile than the broader market.

Summary

Bicycle Therapeutics beats Upexi on 10 of the 17 factors compared between the two stocks.

How does Upexi compare to DiaMedica Therapeutics?

Upexi (NASDAQ:UPXI) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

Upexi has a beta of -0.35, meaning that its share price is 135% less volatile than the broader market. Comparatively, DiaMedica Therapeutics has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market.

5.7% of Upexi shares are held by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are held by institutional investors. 9.0% of Upexi shares are held by insiders. Comparatively, 5.0% of DiaMedica Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Upexi currently has a consensus price target of $8.33, suggesting a potential upside of 779.60%. DiaMedica Therapeutics has a consensus price target of $12.33, suggesting a potential upside of 118.68%. Given Upexi's higher probable upside, research analysts plainly believe Upexi is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upexi	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, DiaMedica Therapeutics had 1 more articles in the media than Upexi. MarketBeat recorded 1 mentions for DiaMedica Therapeutics and 0 mentions for Upexi. Upexi's average media sentiment score of 0.00 equaled DiaMedica Therapeutics'average media sentiment score.

Company	Overall Sentiment
Upexi	Neutral
DiaMedica Therapeutics	Neutral

Upexi has higher revenue and earnings than DiaMedica Therapeutics. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Upexi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upexi	$15.81M	4.21	-$13.68M	-$0.62	N/A
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.71	N/A

DiaMedica Therapeutics has a net margin of 0.00% compared to Upexi's net margin of -874.00%. Upexi's return on equity of -66.70% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upexi	-874.00%	-66.70%	-19.56%
DiaMedica Therapeutics	N/A	-77.15%	-69.23%

Summary

Upexi beats DiaMedica Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Upexi News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UPXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UPXI vs. The Competition

Export

Metric	Upexi	Technology Services Industry	Business Sector	NASDAQ Exchange
Market Cap	$71.67M	$4.20B	$6.67B	$12.46B
Dividend Yield	N/A	2.07%	3.02%	5.34%
P/E Ratio	-1.53	41.66	27.82	23.63
Price / Sales	4.21	55.42	413.66	114.17
Price / Cash	N/A	42.86	24.70	57.17
Price / Book	0.94	4.84	5.86	6.37
Net Income	-$13.68M	$31.69M	$205.22M	$337.36M
7 Day Performance	-20.39%	-1.51%	-0.60%	-2.38%
1 Month Performance	-32.33%	-4.45%	-0.82%	-0.57%
1 Year Performance	-91.55%	23.96%	32.76%	25.53%

Upexi Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UPXI Upexi	2.1737 of 5 stars	$0.95 -7.1%	$8.33 +779.6%	-92.1%	$71.67M	$15.81M	N/A	130	Gap Down
FATE Fate Therapeutics	3.0207 of 5 stars	$2.56 -6.6%	$5.13 +100.4%	+47.8%	$331.03M	$6.32M	N/A	550	News Coverage Gap Down
ORGO Organogenesis	3.0918 of 5 stars	$2.27 -4.0%	$5.75 +153.9%	-16.0%	$330.70M	$512.59M	N/A	950	Positive News Gap Up
ABEO Abeona Therapeutics	3.3108 of 5 stars	$5.70 +1.2%	$19.00 +233.6%	-15.7%	$329.43M	$14.54M	5.76	90
BCYC Bicycle Therapeutics	3.9918 of 5 stars	$4.31 -5.0%	$14.00 +225.2%	-50.6%	$327.41M	$63.50M	N/A	240	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UPXI) was last updated on 6/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Upexi (UPXI) Competitors

UPXI vs. FATE, ORGO, ABEO, BCYC, and DMAC

How does Upexi compare to Fate Therapeutics?

Summary

How does Upexi compare to Organogenesis?

Summary

How does Upexi compare to Abeona Therapeutics?

Summary

How does Upexi compare to Bicycle Therapeutics?

Summary

How does Upexi compare to DiaMedica Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPXI vs. The Competition

Upexi Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Upexi (UPXI) Competitors

UPXI vs. FATE, ORGO, ABEO, BCYC, and DMAC

How does Upexi compare to Fate Therapeutics?

Which has preferable earnings & valuation, FATE or UPXI?

Which has more volatility and risk, FATE or UPXI?

Is FATE or UPXI more profitable?

Do analysts rate FATE or UPXI?

Does the media prefer FATE or UPXI?

Do insiders and institutionals believe in FATE or UPXI?

Summary

How does Upexi compare to Organogenesis?

Do analysts rate UPXI or ORGO?

Which has more volatility & risk, UPXI or ORGO?

Which has better earnings and valuation, UPXI or ORGO?

Is UPXI or ORGO more profitable?

Does the media prefer UPXI or ORGO?

Do insiders & institutionals hold more shares of UPXI or ORGO?

Summary

How does Upexi compare to Abeona Therapeutics?

Do analysts prefer ABEO or UPXI?

Does the media prefer ABEO or UPXI?

Which has better valuation and earnings, ABEO or UPXI?

Is ABEO or UPXI more profitable?

Which has more risk and volatility, ABEO or UPXI?

Do insiders and institutionals have more ownership in ABEO or UPXI?

Summary

How does Upexi compare to Bicycle Therapeutics?

Which has better earnings and valuation, BCYC or UPXI?

Is BCYC or UPXI more profitable?

Does the media refer more to BCYC or UPXI?

Do analysts prefer BCYC or UPXI?

Do insiders and institutionals hold more shares of BCYC or UPXI?

Which has more risk & volatility, BCYC or UPXI?

Summary

How does Upexi compare to DiaMedica Therapeutics?

Which has more risk & volatility, UPXI or DMAC?

Do insiders & institutionals have more ownership in UPXI or DMAC?

Do analysts rate UPXI or DMAC?

Does the media favor UPXI or DMAC?

Which has better earnings and valuation, UPXI or DMAC?

Is UPXI or DMAC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPXI vs. The Competition

Upexi Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools